Zoetis Inc. (NYSE:ZTS) Receives Average Recommendation of “Hold” from Brokerages

Zoetis Inc. (NYSE:ZTS) has received a consensus rating of “Hold” from the seventeen brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $119.50.

A number of research firms have recently weighed in on ZTS. Wall Street Zen lowered Zoetis from a “buy” rating to a “hold” rating in a report on Saturday, May 2nd. Weiss Ratings cut Zoetis from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, June 12th. Barclays cut their price objective on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 1st. JPMorgan Chase & Co. reduced their target price on shares of Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Finally, Citigroup lowered their target price on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating for the company in a report on Monday, May 18th.

Key Stories Impacting Zoetis

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis launched Portela® (relfovetmab), a long-acting pain therapy for cats, in Canada and the European Union, which could support future animal-health revenue and expand its product footprint. Article: Zoetis Launches Portela® (relfovetmab) in Canada and the European Union
• Neutral Sentiment: Several law firms issued reminders that the July 27 deadline is approaching for investors to join a securities class action tied to Zoetis, keeping legal overhang in focus. Article: ZOETIS INC. INVESTORS WITH LOSSES HAVE UNTIL JULY 27, 2026 TO JOIN SECURITIES CLASS ACTION
• Neutral Sentiment: Zoetis was also the subject of unusually large options trading, suggesting elevated investor attention and possible speculation around near-term moves. Article: Zoetis Target of Unusually Large Options Trading
• Negative Sentiment: The stock has recently been trading lower, with market commentary highlighting a decline while the broader market gained, reinforcing the bearish tone around ZTS. Article: Zoetis (ZTS) Stock Dips While Market Gains: Key Facts

Zoetis Price Performance

Shares of NYSE ZTS opened at $74.17 on Friday. Zoetis has a fifty-two week low of $71.47 and a fifty-two week high of $160.48. The stock has a market cap of $31.09 billion, a price-to-earnings ratio of 12.30, a PEG ratio of 1.18 and a beta of 0.75. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The firm’s 50-day simple moving average is $77.28 and its 200 day simple moving average is $104.82.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The company had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a net margin of 27.80% and a return on equity of 66.85%. Zoetis’s revenue for the quarter was up 2.9% on a year-over-year basis. During the same quarter last year, the firm posted $1.48 EPS. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, research analysts anticipate that Zoetis will post 6.87 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date of this dividend is Monday, July 20th. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Buying and Selling at Zoetis

In other news, Director Frank A. Damelio bought 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were purchased at an average price of $75.39 per share, with a total value of $501,343.50. Following the transaction, the director directly owned 21,458 shares in the company, valued at $1,617,718.62. This represents a 44.91% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Paul Bisaro bought 2,000 shares of the business’s stock in a transaction dated Wednesday, May 13th. The stock was acquired at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the purchase, the director directly owned 27,862 shares in the company, valued at approximately $2,114,168.56. The trade was a 7.73% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders bought 11,650 shares of company stock worth $886,384. Insiders own 0.22% of the company’s stock.

Institutional Investors Weigh In On Zoetis

Several large investors have recently made changes to their positions in the business. Tema ETFs LLC raised its stake in shares of Zoetis by 18.9% during the 2nd quarter. Tema ETFs LLC now owns 8,984 shares of the company’s stock worth $646,000 after purchasing an additional 1,431 shares during the period. Handelsbanken Fonder AB grew its position in Zoetis by 10.7% during the second quarter. Handelsbanken Fonder AB now owns 228,467 shares of the company’s stock valued at $16,418,000 after buying an additional 21,990 shares during the period. Fulton Bank N.A. grew its position in Zoetis by 6.1% during the second quarter. Fulton Bank N.A. now owns 11,366 shares of the company’s stock valued at $817,000 after buying an additional 652 shares during the period. Wealthcare Capital Partners LLC increased its holdings in Zoetis by 97.4% during the second quarter. Wealthcare Capital Partners LLC now owns 4,195 shares of the company’s stock worth $301,000 after buying an additional 2,070 shares during the last quarter. Finally, Deane Retirement Strategies Inc. bought a new stake in Zoetis in the second quarter worth about $2,247,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.